SECURITY AGREEMENTSecurity Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionSECURITY AGREEMENT, dated as of March 2, 2022 (this “Agreement”), between Curative Biotechnology, Inc., a Florida limited liability company (the “Company” or the “Debtor” and collectively with any other Debtor from time to time hereunder, the “Debtors”) and the holders of the Company’s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,142,857.14 (the “Note”), signatory hereto, its endorsees, transferees and assigns (individually referred to as, the “Secured Party” and collectively referred to as, the “Secured Party”). Any terms not defined herein shall have the definition ascribed to them in the Purchase Agreement and Note.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”) and the Purchaser identified on the signature pages hereto (including their successors and assigns, the “Purchaser”).
NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Curative Biotechnology Inc • September 9th, 2022 • Biological products, (no disgnostic substances) • New York
Company FiledSeptember 9th, 2022 Industry JurisdictionTHIS 12.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE is one of a series of duly authorized and validly issued 12.5% Original Issue Discount Senior Secured Notes of Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, designated as its 12.5% Original Issue Discount Senior Secured Note due March 2, 2023 (this Note, the “ Note “ and, collectively with the other Notes of such series, the “ Notes”). The Notes shall be convertible into shares of common stock of in the Company in accordance with the terms of the Notes.
LOCK-UP AGREEMENTLock-Up Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionRe: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”)
First Amendment to Transaction DocumentsTransaction Documents • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Contract Type FiledSeptember 9th, 2022 Company IndustryThis First Amendment to the Transaction (this “Amendment”) is entered into as of August 18, 2022, by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431, each a “Party” and collectively the “Parties”. Capitalized terms used herein without definition shall have the meanings ascribed to them in the Securities Purchase Agreement, dated as of March 2, 2022, entered into between the Parties (the “Securities Purchase Agreement”)
SETTLEMENT AGREEMENT AND RELEASESettlement Agreement and Release • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Florida
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionTHIS SETTLEMENT AGREEMENT AND RELEASE (the “Settlement Agreement”), is made and entered into as of this 9th day of August 2021 by and between: (i) FORTIFIED MANAGEMENT GROUP, LLC (“Fortified”) and JODY R. SAMUELS (“Samuels”) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (“Curative” and together with Fortified and Samuels, the “Parties”).
LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • Pennsylvania
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionThis License Agreement (this “Agreement”) is made and is effective this 1st day of October 2021, (the “Effective Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”) and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (“Licensee”), and David Horn, LLC as Licensor to MABT, and their respective legitimate successors and/or assigns. Licensors and Licensee are each referred to as a “Party” and collectively referred to as the “Parties.”
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE EVALUATION OPTION LICENSE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by...Public Health Service • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances) • District of Columbia
Contract Type FiledSeptember 9th, 2022 Company Industry JurisdictionThis Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Royalty Payment Option), and Appendix G (Shipping Information).
FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENTLicense, Funding and Operational Agreement • September 9th, 2022 • Curative Biotechnology Inc • Biological products, (no disgnostic substances)
Contract Type FiledSeptember 9th, 2022 Company IndustryTHIS IS THE FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement for rabies immunotherapy (the “Agreement”) between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc., formerly Connectyx, (“Licensee”) originally executed September 30th, 2020.